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Abstract
The focus of 2013 cholesterol guidelines to prevent atherosclerotic cardiovascular disease (ASCVD) 
released by American College of Cardiology (ACC) and American Heart Association (AHA) is the 
administration of high intensity statin therapy to specific four groups of patients, which were found 
to benefit the most from such therapy. They no longer promote achieving specific LDL-C goals with 
a combination therapy involving statins and other drugs, as advocated by the former ATP-III gui-
delines as well as current guidelines of European Atherosclerosis Society, International Atheroscle-
rosis Society or National Lipid Association. Such approach has been dictated by the strict reliance 
on randomized controlled trials as the only acceptable level of evidence. However, since publication 
of the 2013 ACC/AHA guidelines, cardiovascular benefits of ezetimibe added to statin therapy have 
been established. Moreover, the advent of PCSK9 inhibitors, providing a powerful supplement and/
or alternative to statin therapy, further complicates the therapeutic horizon in dyslipdiemias. It is 
very likely that a new set of ACC/AHA guidelines will be published in 2016, with a return of specific 
LDL-C and Non-HDL-C goals of therapy as well as integration of drugs other than statins. As the 
treatment of dyslipidemias becomes more complex, the need for the subspecialty of clinical lipido-
logy to be officially recognized becomes more evident.
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Introduction
Atherosclerotic cardiovascular disease (ASCVD) includes both coronary artery disease (CAD) as well 
as cerebrovascular disease (CVD)[1]. It remains one of the major killers worldwide [2]. Development 
of ASCVD is directly related to atherosclerotic damage caused over time (cholesterol-years) by various 
ApoB-containing lipoproteins, mostly LDL particles (atherogenic cholesterol). Therefore, lowering 
LDL-C by means of therapeutic lifestyle changes (TLCs) as well as pharmacotherapy is the principal 
approach to prevent ASCVD, both in primary and secondary preventions settings. In the world of LDL 
cholesterol, no doubt remains that “lower is better”.
Impact of the 2013 AHA/ACC Guidelines
In 2013 the American Heart Association (AHA) and American College of Cardiology (ACC) released 
their cholesterol guidelines [1], which in the US have replaced 2001 ATP-III guidelines with 2004 
update [3]. The 2013 ACC/AHA guidelines have dropped the LDL-C and Non-HDL-C targets of the-
rapy, which until now, have been the base of all recommendations. Instead, they emphasized high in-
tensity statin therapy in four “statin-benefit groups” identified using randomized clinical trials (RCTs). 
Those groups include:
1. patients with established ASCVD;
2. patients with LDL-C ≥ 190 mg/dl;
3. patients aged 40-75 with DM and LDL-C 70-189 mg/dl;
4. patients aged 40-75 with 10-year ASCVD risk ≥ 7.5%, as calculated by pooled cohort equations [1].
Treatment based on the new algorithm appears to better identify patients at higher ASCVD risk and 
increases cost-effectiveness of therapy when compared to the ATP-III recommendations with the 2004 
update [4]. However, when using those guidelines some patients may be over-treated (those stratified 
as having ASCVD risk ≥ 7.5% using the pooled cohort equations), others may be undertreated (those 
at high CV risk, who have not achieved sufficient LDL-C lowering on statins alone). The authors of the 
new guidelines acknowledge that they have not provided a comprehensive algorithm to treat all lipid 
disorders, leaving ample space for additional interventions. The new guidelines also propose advanced 
lipid testing and coronary calcium imaging in selected patients with ASVD risk between 5% and 7.5% 
in order to identify additional individuals, which may benefit from statin therapy. It is also another 
myth, that the new guidelines do not advocate lipid testing once statin therapy is initiated. Lipid te-
sting is recommended in order to check compliance and to evaluate whether patients are reaching the 
expected degree of LDL-C lowering (>50% for high intensity statin and 30-50% for medium intensity 
statin) [1]. Insurance companies and managed health care systems in the US have often implemented 
algorithms based on statin prescription alone, oversimplifying ASCVD prevention.
In sharp contrast to the US, the rest of the world still uses targets of therapy. They are included in 
the global recommendations for the management of dyslipidemia issued by the International Athero-
sclerosis Society [5] as well as in the European Atherosclerosis Society guidelines for management of 
dyslipidemias [6]. In the US, National Lipid Association has issued their own recommendations for the 
patient-centered management of dyslipidemia, which include goals of therapy with Non-HDL-C as the 
primary target [7]. 
One can argue, that in a way, the 2013 ACC/AHA guidelines still provide targets of therapy, which are 
no longer expressed as absolute LDL-C levels but as percentages in LDL-C reduction. Indeed, high in-
tensity statin therapy advocated by the 2013 ACC/AHA guidelines is defined as causing an LDL-C drop 
>50%, medium intensity statin therapy is defined as causing a drop between 30-50% and low intensity 
statin therapy as causing a drop < 30% [1]. A hybrid approach is presented by 2012 guidelines from 
19Reviews in Health Care 2016; 7(1)© SEEd All rights reserved
C. WójcikLower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
the Canadian Cardiovascular Society, where the goal of treatment is either to achieve LDL-C levels ≤ 2 
mmol/l or ≥ 50% reduction of LDL-C [8].
The 2013 ACC/AHA guidelines relay strictly on randomized control trials (RCTs) and their meta-
analysis, deliberately ignoring other lines of evidence, such as epidemiological data, subgroup analysis, 
genetic data or expert opinion stemming from basic research. Moreover, those guidelines emphasize 
statin therapy, marginalizing add-on drugs, such as ezetimibe or niacin, which lacked direct RCT evi-
dence of their effectiveness in preventing ASCVD at the time of their publication [1]. This has signifi-
cantly changed in the last two years, with new RCT data regarding ezetimibe and emerging evidence 
on inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9). Niacin, on the other hand, has 
failed to show cardiovascular benefit as an add-on to statin therapy [9,10]. However, it remains a viable 
option for selected patients [11].
Role of ezetimibe
Ezetimibe leads to LDL-C lowering on average 12-25% from baseline by a unique mechanism, through 
inhibition of the Niemann-Pick C1-like protein (NPC1LP), found on apical surface of enterocytes and 
thus inhibition of intestinal absorption of cholesterol as well as plant sterols [12,13]. Since the relea-
se of 2013 ACC/AHA guidelines, hard evidence has appeared, showing that addition of ezetimbe to 
simvastatin improves cardiovascular outcomes. Over a median follow up period of 7 years, the primary 
end-point consisting of combined incidence of CV death, MI, and stroke was significantly lower in the 
ezetimibe/simvastatin arm compared with the simvastatin arm (32.7% vs. 34.7% respectively; number 
needed to treat = 50). However, no significant differences were found in all-cause and CV mortality as 
well as need for coronary revascularization. This effect is presumably mediated by additional lowering 
LDL-C below previously recommended LDL-C targets [14]. Moreover, similar to statins, ezetimibe 
appears to have pleiotropic effects, leading to decrease in intravascular inflammation measured by 
HS-CRP levels [15]. Dual therapy with atorvastatin and ezetimibe leads to greater coronary plaque 
regression than with atorvastatin alone. 
In addition to LDL-C lowering, ezetimibe causes a significant decrease in small dense LDL particles 
as well as remnant particles [16]. Intriguingly, the benefits of ezetimibe may stem from the fact that in 
contrast to statins it does not appear to upregulate PCSK9 [17]. Statins also upregulate the NPC1LP 
transporter, therefore increasing intestinal cholesterol absorption. Through NPC1LP inhibition, eze-
timibe counters this unwanted side effect [12]. Addition of ezetimibe to the lowest dose of a given 
statin usually allows achieving LDL-C reduction similar to the highest dose of the same statin, while 
decreasing the chances for statin-associated side effects. Ezetimibe itself is well tolerated [13]. The main 
barrier to its use has been its relatively high cost and lack of reimbursement by many insurance carriers, 
who applied the statin-centric 2013 ACC/AHA guidelines in their payment rationale.
Role of PCSK9 inhibitors
The summer of 2015 has seen the approval in the US of two new lipid-lowering medications of a com-
pletely new class, called PCSK9 inhibitors (alirocumab [Praluent™, marketed by Sanofi/Regeneron] 
and evolocumab [Repatha™ marketed by Amgen]) [18] with a third agent of this class in clinical trials 
(bocozicumab, developed by Pfizer) [19]. Their development had an unprecedented pace leading from 
discovery of PCSK9 to approved drugs, which potentially will be used by millions.
The LDL receptor (LDL-R) has a central role in regulating LDL-C levels [20,21]. LDL-R binds LDL par-
ticles on hepatocyte surface, leading to the internalization of such complexes into the endosomal com-
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partment. Within endosomes, the LDL-R: LDL-particle complex undergoes dissociation. LDL particles 
are targeted for degradation mediated by lysosomal hydrolases, while LDL-R is recycled to the cellular 
surface [20]. This picture known well from medical student textbooks has been recently changed by the 
discovery that hepatocytes also produce PCSK9, a soluble protein released to the extracellular milieu. 
It eventually becomes associated with the LDL-R:LDL-particle complexes on the plasma membrane 
of hepatocytes. When internalized to endosomes, PCSK9 prevents the dissociation of LDL particles 
from LDL-R. As a consequence, the entire complex is degraded, downregulating LDL-R on hepatocyte 
surface and therefore decreasing the ability of removing LDL-particles from the circulation [22-24].
PCSK9 was originally discovered as a gain-of-function mutation leading to LDL elevation resembling 
classic familial hypercholesterolemia, but without associated mutations in LDL-R or ApoB. Hyperacti-
ve PCSK9 leads to overzealous LDL-R degradation, resulting in a poor clearance of LDL-particles and 
therefore elevated LDL-C levels and associated elevated CV risk [25,26]. Subsequently, several loss-of-
function PCSK9 mutations have been described. In their case, lack of functional PCSK9 leads to ove-
rexpression of LDL-R, resulting in increased LDL-particle clearance and therefore decreased LDL-C 
(~14-40%) levels and associated decrease in CV risk (~47-88%) [24,27]. Other than having this benefi-
cial effect, loss-of-function of PCSK9 did not cause any abnormalities in affected individuals. The latter 
finding has prompted the development of monoclonal antibodies able to bind and inactivate PCSK9. 
As mentioned above, two of such antibodies are already approved for clinical use (alirocumab and evo-
locumab) [18], while a third one (bococizumab) is in phase III clinical trials [19]. Evolocumab, alirocu-
mab and bococizumab have achieved consistent and significant (60-80%) reduction LDL-C levels either 
as monotherapy or when added to statin therapy [19,28-32]. Evolocumab has also been tested in pa-
tients with homozygous familial hypercholesterolemia, where it reduces LDL-C levels by ~30%, except 
in those with null LDL-R mutations [33]. As inferred from such spectacular LDL-C lowering, it can 
be hypothesized that PCSK9 inhibitors will lead to improved CV outcomes. Indeed, post hoc analysis 
of phase 3 studies of evolocumab and alirocumab have shown an additional 48-53% reduction of CV 
events when added to statin therapy [34,35]. The CV benefits of those new drugs are going to be further 
investigated in large multicenter trials focused on evaluation of cardiovascular benefits [29,36,37].
Safety and tolerability of PCSK9 inhibitors appears to be similar to that of placebo, with rare injection 
site reactions and flu-like symptoms lasting several hours being the most common side effects [29,31]. 
The only concerning findings was the rate of neurocognitive adverse events which was found to be 
higher with evolocumab and alirocumab groups than with placebo in phase 3 trials [34,35].
An additional benefit of PCSK9 inhibitors is their ability to reduce Lp(a), an independent familial risk 
factor for ASCVD, which is not affected at all by statins [29-31,38]. Cholesterol associated with Lp(a) 
can contribute in some patients approximately 30-45% to measured LDL-C levels as a percentage of its 
mass [38]. Evolocumab is able to reduce Lp(a) from 18 to 36% in a dose-dependent manner [30,31]. 
Alirocumab use also resulted in a significant reduction in Lp(a) ~ 30% from baseline compared with 
placebo. Intriguingly, reductions in Lp(a) only weakly correlated with the magnitude of low-density 
lipoprotein cholesterol lowering [39].
New guidelines on the horizon
The landscape of ASCVD prevention is changing dramatically in front of our eyes. There is no doubt 
that statins will remain the cornerstone of therapy as their benefit, especially for the four groups of 
patients highlighted by the 2013 ACC/AHA guidelines, is well established in multiple RCTs [1]. Ezeti-
mibe will likely become the recommended first line add-on on top of statins, leaving PCSK9 inhibitors 
as the last resource. 
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Without set goals of therapy, it is hard to envision a rational algorithm for treatment escalation, espe-
cially one involving the addition of expensive but very powerful injectable drugs such as PCSK9 inhibi-
tors. Regardless of the approach, the number of patients requiring those drugs may be very significant, 
if we consider statin-intolerance as an indication for their use. Most patients tolerate statins well, but 
up to 29% experience side effects (primarily muscle-related) contributing to diminished compliance or 
discontinuation of statin therapy and subsequent increase in cardiovascular risk [40]. However, statin 
intolerance if often very subjective, as it has been recently shown that up to 70% of patients previously 
characterized as “statin-intolerant” actually tolerate well 20 mg of atorvastatin daily, if they are not 
aware that they are taking a statin [41].
In the new guidelines, not only the old LDL-C goals of therapy are likely to return, but also a new LDL-
C target of ≤ 40 mg/dl may emerge for the very high-risk patients. It is reasonable, that new guidelines 
will provide a hybrid approach between that of ATP-III and 2013 ACC/AHA guidelines, advocating 
lipid lowering therapy tailored to achieve either ≤ 70 mg/dl LDL-C levels OR ≥ 50% reduction of LDL-
C, similar to the approach of 2012 CCS guidelines [8]. 
Moreover, rather than focusing solely on LDL-C, Non-HDL-C may become the main target of therapy, 
as it better approximates cardiovascular risk [7]. This is due to the fact that Non-HDL-C correlates bet-
ter with levels of LDL-particles. The latter can be discordant with LDL-C levels in as many as ~30% of 
patients. There is also some degree of discordance between Non-HDL-C and LDL-particles, which may 
be also measured directly or by measurement of ApoB levels, providing alternate targets for therapy 
[42,43]. However, their measurement is expensive and requires advanced testing, while Non-HDL-C 
can be directly calculated from standard non-fasting or fasting lipid panel. The use of Non-HDL-C as 
the primary target of therapy has been already advocated by the National Lipid Association [7]. Both 
Non-HDL-C and ApoB are alternate targets in the CCS guidelines [8]. 
Questions for further research
The causative relation between atherosclerosis and levels of atherogenic cholesterol allows to hypothe-
size, that the use of PCSK9 inhibitors will likely lead to significant reduction in ASCVD mortality and 
morbidity. Indeed, post hoc analysis from phase III trials have shown 48-53% reduction of CV events 
when PSCK9 inhibitors are added to statin therapy [34,35], but full data are still lacking [44]. Several 
large cardiovascular outcome trials are under way to address this issue. The ODYSSEY Outcomes trial 
will test the effects of alirocumab on the combined endpoint of CHD death, MI, ischemic stroke, or 
hospitalization for unstable angina in 18,000 patients with a starting LDL-C ≥ 70 mg/dl randomized 
1-16 weeks post-ACS who have been treated with statin therapy. ODYSSEY outcomes trial will be fi-
nalized by March of 2018 [36]. The FOURIER trial will test the effects of evolocumab on the combined 
end-point of CV death, MI, stroke, hospitalization for unstable angina or coronary revascularization in 
22,500 patients with previous MI, stroke or peripheral arterial disease with a starting LDL-C ≥ 70 mg/
dl who have been treated with atorvastatin 20 mg or higher or equivalent therapy. It will be finalized 
by December 2017 [29]. Finally, the SPIRE trials (SPIRE I and II) will test the effects of bococizumab 
on the combined endpoint of CV death, MI, stroke or urgent revascularization. SPIRE I will focus on 
12,000 patients with LDL-C between 70 and 99 mg/dl, while SPIRE II will focus on 6300 patients with 
LDL-C ≥ 100 mg/dl, all of them on appropriate baseline lipid lowering therapy. The outcome of the 
SPIRE trials will be known by August 2017. The completion of those trials will provide ample evidence 
to include PCSK9 inhibitors in future guidelines. It will also address the potential safety concerns [44]. 
The cost of therapy with monoclonal antibodies for a common disease, such as dyslipidemia, will have 
a likely impact on insurance policies and reimbursement [37]. In an attempt to rationalize their use, 
their prescription may be relegated from primary care physicians and cardiologists to subspecialists in 
clinical lipidology.
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The review in brief
The novel approach of the 2013 ACC/AHA cholesterol guidelines to prevent ASCVD consisted in 
abandoning LDL-C goals of therapy and focusing on initiation on medium to high intensity statin 
therapy in groups of patients with high CV risk [1]. However, this approach is no longer consistent 
with emerging evidence of cardiovascular benefits of ezetimibe [14] and PCSK9 inhibitors [45]. There 
is an urgent need for new guidelines, which will integrate the rational use of this new class of agents. 
As our armamentarium of lipid lowering drugs grows and the landscape of cardiovascular prevention 
becomes more complicated, it is becoming clear that a population-based “one size fit all” solution to 
cardiovascular prevention may not be optimal. Personalization of lipid lowering therapy and its fitting 
to individualized CV risk requires significant expertise, heralding the imminent approval of clinical 
lipidology as the new medical subspecialty in the US.
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